Loomis, Sayles & Company
VNDA icon

Loomis, Sayles & Company’s Vanda Pharmaceuticals VNDA Stock Holding History

Loomis, Sayles & Company’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-391
Closed -$9K – 944
2018
Q3 		$9K Hold
391
– – ﹤0.01% 828
2018
Q2 		$7K Hold
391
– – ﹤0.01% 854
2018
Q1 		$7K Buy
+391
New +$6.54K ﹤0.01% 847

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Loomis, Sayles & Company's VNDA Position: Q4 2018 in Review

Loomis, Sayles & Company sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 391 shares — an estimated $9K sold.

Loomis, Sayles & Company first reported a position in VNDA in Q1 2018 and held it in 3 quarters. The position peaked at $9K in Q3 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

  • Loomis, Sayles & Company reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 391 Vanda Pharmaceuticals shares in Q4 2018, an estimated $9K.
  • Loomis, Sayles & Company first reported a position in Vanda Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Loomis, Sayles & Company's Vanda Pharmaceuticals position peaked at $9K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Loomis, Sayles & Company's 13F filing for Q4 2018, filed 14 Feb 2019.